Polycystic ovary syndrome (PCOS), affecting around 170 million women globally, is undergoing a significant rebranding. The chronic hormonal disorder will now be referred to as polyendocrine metabolic ovarian syndrome (PMOS). This change aims to enhance awareness, diagnosis, and treatment options for women dealing with this condition.
Significance of the Name Change
This new designation was announced at the European Congress of Endocrinology in Prague and published in The Lancet. Experts believe that PMOS better reflects the disorder’s underlying hormonal and metabolic issues rather than just its ovarian aspects.
Donna Vine, a prominent researcher at the University of Alberta, expressed optimism about the rebranding. She stated that the change could lead to improved patient care and a deeper understanding of the disease.
Understanding PMOS
In Canada, a diagnosis of PMOS requires meeting two of the following three criteria:
- Irregular menstrual cycles
- Overproduction of testosterone (hyperandrogenism) resulting in acne, excessive hair growth, or baldness
- Ultrasound evidence of increased ovarian follicles or elevated anti-müllerian hormone levels
Women affected by PMOS may experience a variety of symptoms, including:
- Irregular periods
- Acne or oily skin
- Hair thinning or excessive hair growth
- Challenges with fertility
- Increased risk of anxiety, depression, and eating disorders
Associated Health Risks
Beyond reproductive issues, PMOS increases the risk of several serious health conditions, including:
- Obesity
- High blood pressure
- Type 2 diabetes
- Heart disease
- Endometrial cancer
Why the Change from PCOS?
The term PCOS has been criticized for its misleading connotation of cysts. Experts, including Dr. Roland Antaki from the University of Montreal, argue that the condition primarily involves hormonal imbalances rather than cyst formation. PMOS accurately reflects the diverse symptoms women experience and emphasizes the metabolic implications.
The Impact of Rebranding
Students and advocates like Sankirthana Dyapa are hopeful that PMOS will prompt a better understanding of the disorder. The previous name focused too narrowly on reproductive aspects, which often marginalized other symptoms. Dyapa co-founded McMaster University’s PCOS Society to raise awareness and support women affected by this condition.
Overall, the transition to PMOS represents a crucial step toward a more comprehensive understanding of the disorder. It aims to ensure that women receive the care they deserve, addressing all aspects of their health. This rebranding may aid in closing the gap in awareness and treatment for a condition that affects millions globally.
